BMS 582949 – 5 mg

Brand:
Cayman
CAS:
623152-17-0
Storage:
-20
UN-No:
De Minimis - 3077 / 9

BMS 582949 is an orally bioavailable p38α MAP kinase inhibitor (IC50 = 13 nM in an enzyme assay).{39188} It also inhibits TNF-α production in human peripheral blood mononuclear cells (PBMC; IC50 = 50 nM). When administered at a dose of 5 mg/kg in mice, it decreases LPS-induced TNF-α production up to 89% compared to vehicle. BMS 582949 reduces paw swelling in a rat adjuvant arthritis model when administered once per day (1, 10, or 100 mg/kg) or twice per day (1 or 5 mg/kg).  

 

Available on backorder

SKU: 22892 - 5 mg Category:

Description

A p38α MAP kinase inhibitor (IC50 = 13 nM); inhibits TNF-α production in PBMCs (IC50 = 50 nM); reduces LPS-induced TNF-α production up to 89% in mice at 5 mg/kg; reduces paw swelling in a rat adjuvant arthritis model when administered once per day (1, 10, or 100 mg/kg) or twice per day (1 or 5 mg/kg),


Formal name: 4-[[5-[(cyclopropylamino)carbonyl]-2-methylphenyl]amino]-5-methyl-N-propyl-pyrrolo[2,1-f][1,2,4]triazine-6-carboxamide

Synonyms: 

Molecular weight: 406.5

CAS: 623152-17-0

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|p38 MAPK||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Immunology & Inflammation|Autoimmunity|Rheumatoid Arthritis||Research Area|Immunology & Inflammation|Innate Immunity